Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Clinical trial NCT02521051 · TERMINATED
Trial details
- NCT number
- NCT02521051
- Sponsor
- Massachusetts General Hospital
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-28
- Primary completion
- 2022-04-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.